Superior Planning, LLC’s PTC Therapeutics PTCT Stock Holding History

Superior Planning, LLC’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.98K	Buy	+46	New	+$3.35K	﹤0.01%	1412

Other funds holding PTCT

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Boston Partners Boston, Massachusetts $111B AUM 30.48% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Superior Planning, LLC's PTCT Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in PTC Therapeutics (PTCT) in Q3 2026: 46 shares worth $2.98K. The stake represents ﹤0.01% of the portfolio and ranks #1412 among its holdings.

227 funds tracked by Wall St. Rank hold PTCT as of Q3 2026.

Superior Planning, LLC held 46 shares of PTC Therapeutics worth $2.98K as of Q3 2026.
PTC Therapeutics was a new Superior Planning, LLC position in Q3 2026.
PTC Therapeutics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1412 holding.
227 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.